BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous LeukemiaWilliam E. Pierceall, Michael Andreeff, Steven M. Kornblau et al.|Molecular Cancer Therapeutics|2013Cited by 32
Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating DrugsJo Ishizawa, Michael Andreeff, Kensuke Kojima et al.|PLoS ONE|2015Cited by 24
Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and DexamethasoneJames Croft, Martin Kaiser, Andrew Hall et al.|Blood|2018Cited by 8
Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker TrialJames Croft, Martin Kaiser, Andrew Hall et al.|Blood|2019Cited by 4
PF588 SIGNIFICANT POM EFFECT ON THE IMMUNE‐CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMARao Prabhala, Nikhil C. Munshi, Mariateresa Fulciniti et al.|HemaSphere|2019Cited by 0